Company intelligence / Profile preview

Ethris GmbH

Ownership: Private
Development stage: Other

Overview

Ethris recently completed a Phase 1 clinical trial of its lead mRNA therapeutic candidate, ETH47, in healthy volunteers. The trial demonstrated that nasal administration of ETH47 was generally safe and well-tolerated at all dose levels with no serious or severe adverse events. The company plans to initiate a Phase 2a clinical trial in Q2 2025 to evaluate ETH47's ability to reduce symptoms after rhinovirus infection in asthma patients.

Therapeutic areas: PulmonologyRare DiseasesInfectious Diseases
Modalities: mRNA therapeuticsmRNA vaccines
Industry: Biotech

Drug pipeline

4 assets

ETH47

3 more assets in the full pipeline.

Partnerships

AstraZeneca and MedImmune (five-year strategic research collaboration)DIOSynVax (collaboration for betacoronavirus vaccine)CEPI (Coalition for Epidemic Preparedness Innovations)Cipla (EU) (investor)

Beyond the preview

Go deeper on Ethris GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ethris GmbH.